Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer

Summary

The purpose of this study is to determine whether the new RNActive®-derived prostate cancer vaccine CV9104 prolongs survival in patients with asymptomatic or minimally symptomatic metastatic prostate cancer that is castrate resistant.

Timeline

Start

2012-08

Primary completion

2016-08

Completion

2017-01

Outcome

Outcome not reported

Stopped: “Follow up period after primary analysis was prematurely stopped because more mature data will not impact the study outcome”

Drugs

Indications